Exelixis
EXEL
64.63
-1.20
-1.82%
Exelixis
US · EXEL
#1156 by market cap
Listed 1970
64.63
-1.20
-1.82%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
Recent news
-
Company notice
Exelixis | 4: Statement of changes in beneficial ownership of securities-Officer Haley Patrick J.SEC · 2026/5/20
-
Rating change
BofA Securities Maintains Exelixis(EXEL.US) With Sell Rating, Maintains Target Price $41Market Newswire · 2026/10/9
-
Citizens JMP Maintains Exelixis(EXEL.US) With Buy Rating, Raises Target Price to $65Market Newswire · 2026/10/19
-
Rating change
Exelixis Is Maintained at Buy by HC Wainwright & Co.Dow Jones · 2026/11/2
-
Company notice
Exelixis | 4: Statement of changes in beneficial ownership of securities-Director Heyman Tomas J.SEC · 2026/5/30
-
Rating change
William Blair Maintains Exelixis(EXEL.US) With Buy RatingMarket Newswire · 2026/9/11
-
Company notice
Exelixis | 4: Statement of changes in beneficial ownership of securities-Officer Haley Patrick J.SEC · 2026/5/23
-
Company notice
Exelixis | 4: Statement of changes in beneficial ownership of securities-Officer Senner Christopher J.SEC · 2026/3/3
-
H.C. Wainwright Maintains Exelixis(EXEL.US) With Buy Rating, Raises Target Price to $78Market Newswire · 2026/11/2
-
Rating change
Truist Financial Maintains Exelixis(EXEL.US) With Hold RatingMarket Newswire · 2026/9/14
-
Rating change
Analysts Offer Insights on NA Companies: Exelixis (EXEL) and Resolution Minerals Ltd. Sponsored ADR (RML)TipRanks · 2026/9/14
-
Rating change
Stifel Maintains Exelixis(EXEL.US) With Hold RatingMarket Newswire · 2026/9/13
-
TD Cowen Maintains Exelixis(EXEL.US) With Buy Rating, Raises Target Price to $76Market Newswire · 2026/10/30
-
Rating change
Goldman Sachs Maintains Exelixis(EXEL.US) With Buy Rating, Maintains Target Price $64Market Newswire · 2026/8/6
-
Exelixis Q3 Adj. EPS $0.94 Beats $0.80 Estimate, Sales $658.696M Beat $646.510M EstimateBenzinga · 2026/10/30
-
Rating change
Exelixis Price Target Raised to $78.00/Share From $56.00 by HC Wainwright & Co.Dow Jones · 2026/11/2
-
Rating change
Truist Financial Maintains Exelixis(EXEL.US) With Hold Rating, Raises Target Price to $56Market Newswire · 2026/7/7
-
Rating change
Goldman Sachs Maintains Exelixis(EXEL.US) With Buy Rating, Raises Target Price to $64Market Newswire · 2026/7/23
-
HC Wainwright & Co. Maintains Buy on Exelixis, Raises Price Target to $78Benzinga · 2026/11/2
-
Company notice
Exelixis | 4: Statement of changes in beneficial ownership of securities-Officer Senner Christopher J.SEC · 2026/5/20
-
Rating change
Truist Financial Downgrades Exelixis(EXEL.US) to Hold Rating, Raises Target Price to $54Market Newswire · 2026/6/25
-
Rating change
Stifel Maintains Exelixis(EXEL.US) With Hold Rating, Announces Target Price $47Market Newswire · 2026/5/7
-
Rating change
Analysts Offer Insights on Healthcare Companies: Caris Life Sciences, Inc. (CAI) and Exelixis (EXEL)TipRanks · 2026/7/2
-
Rating change
Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL), Kiora Pharmaceuticals (KPRX) and MAIA Biotechnology, Inc. (MAIA)TipRanks · 2026/6/22
-
Rating change
H.C. Wainwright Maintains Exelixis(EXEL.US) With Buy Rating, Maintains Target Price $56Market Newswire · 2026/7/2
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 20:02:41 · For reference only, not investment advice and not tailored to your situation.
Exelixis discussion 0 comments